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Abstract
The type III secretion system (T3SS) is employed to deliver effector proteins to the cytosol of eukaryotic hosts by multiple
species of Gram-negative bacteria, including Pseudomonas aeruginosa. Translocation of effectors is dependent on the
proteins encoded by the pcrGVHpopBD operon. These proteins form a T3S translocator complex, composed of a needle-tip
complex (PcrV), translocons (PopB and PopD), and chaperones (PcrG and PcrH). PcrV mediates the folding and insertion of
PopB/PopD in host plasmic membranes, where assembled translocons form a translocation channel. Assembly of this
complex and delivery of effectors through this machinery is tightly controlled by PcrV, yet the multifunctional aspects of this
molecule have not been defined. In addition, PcrV is a protective antigen for P. aeruginosa infection as is the ortholog, LcrV,
for Yersinia. We constructed PcrV derivatives containing in-frame linker insertions and site-specific mutations. The
expression of these derivatives was regulated by a T3S-specific promoter in a pcrV-null mutant of PA103. Nine derivatives
disrupted the regulation of effector secretion and constitutively released an effector protein into growth medium. Three of
these regulatory mutants, in which the linker was inserted in the N-terminal globular domain, were competent for the
translocation of a cytotoxin, ExoU, into eukaryotic host cells. We also isolated strains expressing a delayed-toxicity
phenotype, which secrete translocators slowly despite the normal level of effector secretion. Most of the cytotoxic
translocation-competent strains retained the protective epitope of PcrV derivatives, and Mab166 was able to protect
erythrocytes during infection with these strains. The use of defined PcrV derivatives possessing distinct phenotypes may
lead to a better understanding of the functional aspects of T3 needle-tip proteins and the development of therapeutic
agents or vaccines targeting T3SS-mediated intoxication.
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Introduction
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen
responsible for severe nosocomial pneumonias, acute infections of
immunocompromised individuals, and chronic infections of cystic
fibrosis patients [1,2]. Morbidity and mortality is due to a
combination of host factors, the severity of tissue injury, and the
intrinsic resistance displayed by P. aeruginosa to many therapeutic
drugs [3,4]. A major virulence factor used by P. aeruginosa during
infection is the type III secretion system (T3SS) [2,5–7]. Many
Gram-negative pathogens employ T3SSs, which can be likened to
a molecular syringe, to inject toxins directly into eukaryotic cells
[8,9]. Four known P. aeruginosa T3SS toxins, ExoS, ExoT, ExoU,
and ExoY, have been identified to date. ExoS and ExoT interfere
with eukaryotic cell signaling pathways and host cytoskeletal
architecture by their bifunctional Rho GAP and ADP-ribosyl-
transferase activities [10–13]. ExoU functions as a phospholipase
A2 [14]. ExoY is an adenylyl cyclase that shares homology to the
edema factor of the anthrax toxin [15]. Of the four identified
effectors, ExoU and ExoS are cytotoxic. The intracellular delivery
of these enzymes and their interaction with eukaryotic cofactors is
highly correlated with the dissemination of bacteria from the initial
sites of infection and the induction of sepsis [5,16–18].
The P. aeruginosa T3SS components (Psc) belong to the family of
proteins that include orthologs encoded by Yersinia (Ysc) and by
Aeromonas (Asc) [19–21]. Intoxication of mammalian cells by P.
aeruginosa requires the products of the pcrGVHpopBD operon
[7,16,22]. PcrV, PopB, and PopD are classified as translocators
and mediate the injection of the effectors into eukaryotic cells or
contact-dependent lysis of erythrocytes [23–26]. PopB and PopD
are hydrophobic proteins that interact with or insert into
membrane lipids, forming a channel called the translocon
[22,24,27]. The translocon assembly is necessary for delivery of
T3S effectors across the eukaryotic plasma membrane into the
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philic protein forming the T3-needle tip complex, which is
required for appropriate assembly and insertion of PopB and
PopD into host membranes [24,27]. Strains carrying a pcrV-null
mutation are noncytotoxic due to the inability to assemble the
translocon [24,29]. Complementation with a wild-type copy of the
gene restores type III translocation and cytotoxicity. These results
suggest that PcrV is involved in the regulation of effector
translocation [29].
Of these translocator proteins only PcrV is an important
protective antigen against T3SS-mediated Pseudomonas infection
[29–31]. Active immunization with recombinant PcrV protects
mice from lethal infection even under induced-leukocytopenia
conditions [29,32]. Passive protection against cellular intoxication,
lung injury, and bacteremia due to P. aeruginosa infection in animal
models was demonstrated with polyclonal antiserum or affinity-
purified antibodies, a monoclonal antibody (Mab166), and a
humanized F(ab9)2 single chain antibody against PcrV
[29,30,32,33]. These data provide further evidence for the critical
role of PcrV in translocation events and suggest that PcrV is
exposed on the bacterial surface rendering it accessible to antibody
neutralization.
In this study we used an unbiased genetic approach to further
define the functional domains of PcrV based on phenotypic
analyses. A transposon-based system was used to randomly insert
an in-frame linker into PcrV, and the derivatives were expressed
under T3SS regulation in pcrV-deleted PA103. Based on
phenotypic analyses, we grouped the linker-insertion and site-
specific mutants into 4 classes. Each class of mutants exhibited
different functional properties, suggesting that these derivative
molecules will be useful towards understanding the multifunctional
aspects of T3S tip proteins.
Results
Protein structure modeling of PcrV
Recent progress using electron microscopy, molecular genetics,
and structural biology approaches has increased our understand-
ing of the mechanistic aspects of the T3SS translocation
machinery. Visualization of the Ysc family members of needle-
tip complexes by scanning transmission electron microscopy
demonstrated that these molecules consist of three structural
domains called the head, neck, and base [34]. The crystal structure
of LcrV from Yersinia indicates that the protein has an overall
dumbbell shape with a ‘‘grip’’ formed by the antiparallel coiled-
coil of two long a-helices and globular domains at each end [35].
When the amino-acid sequences of Y. pestis LcrV and PcrV from
several P. aeruginosa strains were aligned, the proteins possess 37 to
41% identity (Fig. 1A) and have sufficient similarity to produce
superimposable structural models, with the model for PcrV shown
in Fig. 1B (Swiss Model server, http://www.expasy.org) [36]. The
LcrV structure information in this study, modeled from the data
deposited in PBD (1r6f chain A), demonstrated subtle differences
from the original crystallography study by Derewanda et al. [35].
The newer version of the modeling program (Swiss-protein, 2008)
did not assign the previously predicted two a-helices, a3 and a8, in
LcrV, thus the numerical nomenclatures of helices in this study are
not identical to the original model.
Broz et al. determined that the N-terminal globular domain of
three Ysc-family tip proteins, LcrV, PcrV, and AcrV (Aeromonas),
forms the base of the tip complex that faces the Yersinia needle
protein, YscF [34]. Based on the tertiary structure models, the
base structure of PcrV corresponds to the N-terminal a-helices
and b-sheets, a1, b1, a2, a3, b2, a4, and a5 (Fig. 1A and B). The
C-terminal globular domain of LcrV forms the head of the tip
complex and the neck is presumably the intramolecular coiled-
coil region [34]. LcrV and PcrV contain a high structural
similarity in the long coiled-coil region, which is a neck structure
formed by a6 and a11 of PcrV (Fig. 1B). The C-terminal globular
domain of PcrV is composed of several short a-helices and b-
sheets (b3, a7, a8, a9, b4, and a10) with loop structures between
(Fig. 1A and B).
Scanning linker mutagenesis of PcrV
To understand the structure-function relationships of the
multifunctional protein PcrV, we used a genetic approach to
randomly introduce a 57-bp linker throughout the molecule. The
plasmid containing pcrV with a type III promoter for exoS, pUCP-
pS-pcrV (amp
r), was mutagenized using an in vitro transposition
system, which results in the insertion of a kanamycin marker (kan
r)
flanked by NotI sites. Approximately 129 plasmids that expressed
both kan
r and amp
r in E. coli were screened by restriction mapping
to identify the insertion within the pcrV coding region. Removal of
the kan
r cassette by digestion with NotI and religation leaves 57
base pairs, resulting in an in-frame insertion of the 19-amino-acid
EZ linker. Twenty-eight distinct in-frame insertion mutants were
isolated. Derivatives are designated as EZ followed by the amino
acid location where the linker was inserted or where the original
PcrV amino-acid residue was substituted with another residue
(Table 1 and 2). Insertions were localized within the predicted
alpha helices of PcrV, a1, a3, a4, a5, a6 and a11 as well as in
regions flanking these structural features (Fig. 1A and B). The
pUCP-pS-pcrV plasmids carrying a linker insertion were trans-
formed into a pcrV-null strain of P. aeruginosa, PA103DpcrV, and
expression of the PcrV::EZ proteins was assessed by Western blot
analysis with polyclonal anti-PcrV IgG. Compared to PcrV
expressed from a complementation construct, derivatives had a
slightly altered mobility in SDS-PAGE due to the additional 19
residues and the various amino acid sequences encoded within the
insertion (Table 2). The sequence within the linkers differed by the
target site duplication and three possible open reading frames
based on the site of transposition (insertion frames are shown in
Table 2).
Cytotoxicity and secretory-regulation phenotypes of
PcrV::EZ expressed in a pcrV-null strain
In cell culture systems, a pcrV-deletion strain (PA103DpcrV)
releases effector proteins into the culture medium and is unable to
intoxicate host cells (Fig. 2A and [24,29]). Expression of wild-type
PcrV in PA103DpcrV restores the regulation of type III secretion
and cytotoxicity (Fig. 2A). We screened PA103DpcrV strains
expressing PcrV::EZ in an acute cytotoxicity assay that measures
the ability of P. aeruginosa to inject a cytotoxin, ExoU. During tissue
culture infections, the translocation of this phospholipase toxin
results in cell death and loss of the monolayer. The cytotoxic
phenotype of derivative strains was screened by a crystal violet
retention assay using HeLa-cell monolayers (data not shown). This
initial screening step identified 6 nontoxic mutants out of the total
of 28 derivatives. We further examined the kinetic patterns of
intoxication of HeLa cells using a defined multiplicity of infection
(MOI) of 5. The release of lactate dehydrogenase (LDH) within a
3–5 h infection period is a measure of cellular permeability due to
the enzymatic activity of ExoU [14]. LDH release was clearly
evident when cytotoxic strains were compared with noncytotoxic
mutants (compare open/gray to closed symbols in Fig. 2A). There
was no significant difference in the overall kinetics of LDH release
among a wild-type strain and all of the cytotoxic linker mutants
(representative strains are shown in Fig. 2A).
Functional Mapping of Pseudomonas aeruginosa PcrV
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aeruginosa is grown in the presence of a calcium chelator,
nitrilotriacetic acid (NTA, [37]). Effector proteins as well as the
proteins required for translocation are secreted and accumulate
in the extracellular growth medium under the low-calcium
conditions [7]. In the absence of a chelator, secretion of effectors
is controlled via transcriptional inhibition of the loci involved in
the process [7,16,38]. The pcrV-null strain, PA103DpcrV, releases
type III effectors even in the absence of induction, suggesting that
the secretion apparatus is deregulated and constitutively releasing
those proteins [29,38]. Calcium-mediated regulation of T3SS is
restored by complementation with pcrV in trans [38]. All of our
EZ-linker mutants secreted similar amounts of ExoU after growth
in the presence of NTA (data not shown). An insertion that blocks
secretion of ExoU was not isolated. Nine mutants were calcium
insensitive and constitutively secreted ExoU even in the absence
of the inducer (Fig. 2B). The expression of these derivatives
within bacterial cells was confirmed (Fig. S1). The deregulated-
secretion phenotype was defined by an enhanced level (.40%) of
ExoU release as compared to the PcrV-complemented strain
(Fig. 2B). The remaining derivatives demonstrated a cytotoxic
phenotype with a pattern of regulated secretion similar to the
complemented strain, which are classified as class I mutants
(Fig. 2B and Table 3). Insertion sites in this class of the derivatives
were generally located in the N- and C-terminal globular
domains with exceptions of EZ154 and EZ155, in which the
linker was located at the top region of a-6, one of the coiled-coil
helices (Fig. 1 and Table 3).
Insertions associated with the disruption of secretory
regulation mapped to two distinct areas of PcrV (Fig. 2B).
One set (EZ119, EZ120, EZ131, EZ134, EZ138, and EZ279)
mapped to the end of the globular domain and to the central
Table 1. Pseudomonas aeruginosa strains used in this study.
Strain Relevant characteristics/description
PA103 Wild-type cytotoxic strain, expresses type III proteins and translocates effectors, ExoU and ExoT.
PA103+pUCP-pS-pcrV Wild-type strain harboring a plasmid copy of pcrV under control of the type III exoS promoter.
Cytotoxic.
PA103exsAV+pUCP Type III knockout strain, mutation in the type III regulatory gene, exsA, prevents activation of the
type III secretion system. Noncytotoxic.
PA103DpcrV+pUCP (PA103DV+pUCP) Nonpolar pcrV deletion harboring a plasmid. Noncytotoxic and constitutive secretion.
PA103DpcrV+pUCP-pS-pcrV
(PA103DV+pcrV)
Complemented mutant harboring a plasmid copy of pcrV under control of the type III exoS
promoter. Cytotoxic.
PA103DV+pUCP-pS-exoUS142A
(PA103DV+exoU-S142A)
Nonpolar pcrV mutant harboring a plasmid copy of exoU with a point mutation at its catalytic site.
Noncytotoxic and constitutive secretion.
PA103DpopB (PA103DB) Nonpolar popB deletion. Noncytotoxic.
PA103DpopB+pUCP-pS-popB
(PA103DB+popB)
Complemented mutant harboring a plasmid copy of popB. Cytotoxic.
PA103DUT+pUCP
(PA103DUT+pUCP)
ExoU and ExoT knockout strain harboring a plasmid. Regulated secretion and noncytotoxic.
PA103DUT+pUCP-pS-exoUS142A
(PA103DUT+exoU-S142A)
DUT strain harboring a plasmid copy of exoU with a point mutation at its catalytic site. Regulated
secretion and noncytotoxic.
PA103DpcrV+pUCP-pS-pcrV-EZ
(PA103DV+EZ)
EZ16, EZ28, EZ77, EZ96, EZ101, EZ104, EZ105, EZ107, EZ109,
EZ113, EZ116, EZ154, EZ155, EZ179, EZ180, EZ198, EZ202,
EZ204, EZ214
Nonpolar pcrV mutant harboring a plasmid copy of pcrV::EZ linker.
Regulated secretion and cytotoxic.
PA103DV+EZ44, EZ52, EZ64 Deregulated secretion and cytotoxic.
PA103DV+EZ119, EZ120, EZ131, EZ134, EZ138, EZ279 Deregulated secretion and noncytotoxic.
PA103DpcrV+pUCP-pS-pcrV-L63A or D133A (PA103DV+L63A or
D133A)
Nonpolar pcrV mutant harboring a plasmid copy of pcrV with a point mutation at amino acid residue
63 or 133. Regulated secretion with delayed cytotoxicity.
PA103+pUCP-pS-pcrV-EZ (PA103+EZ) EZ44, EZ52, EZ64, EZ119,
EZ120, EZ131, EZ134, EZ138, EZ279
Wild-type strain harboring a plasmid copy of pcrV::EZ-linker.
Regulated secretion and cytotoxic.
PA103+pUCP-pS-pcrV-L63A or D133A
(PA103+L63A or D133A)
Wild-type strain harboring a plasmid copy of pcrV with a point mutation at amino acid residue 63 or
133. Regulated secretion and cytotoxic.
doi:10.1371/journal.pone.0018356.t001
Figure 1. Location of the EZ-linker insertions in PcrV. (A) Alignment of amino acid sequences and predicted secondary structures of PcrV and
Y. pestis LcrV. Linker insertion sites are indicated as a triangle tag with a residue number. Site-specific point mutations are indicated with red shaded
bars. Colors of predicted secondary structures (a-helix, bar; b-sheet, arrow) in PcrV correspond to the colors in the 3D models in (B). Secondary
structures of LcrV are shown below the alignment (gray). N-terminal regions in the LcrV crystal structure possessing no interpretable electron density
are indicated in light gray. For crystallization of LcrV, charged residues at 40 to 42 and a cysteine residue at 273 (shown in red) were replaced with
alanine and serine residues, respectively. (B) Location of linker insertions in the tertiary structure models of wild-type PcrV. For modeling, LcrV (1r6f
chainA) was used as a template in Swiss Model. Predicted secondary structures are colored in a succession mode. Location of linker insertions is
shown as white highlights in a-helices and magenta shading in b-sheets and loops. Left versus right panels: front and back views of PcrV (rotated
180u).
doi:10.1371/journal.pone.0018356.g001
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EZ64) mapped to the predicted N-terminal globular domain.
Interestingly, the derivatives with the constitutive-secretion
phenotype segregated into noncytotoxic and cytotoxic groups.
Insertions adjacent to or within the coiled-coil region (1
st group)
prevented both translocation and regulated secretion of ExoU
(gray boxes in Fig. 2B). In contrast, insertions in the N-terminal
globular domain (2
nd group) retained the cytotoxic phenotype
(dotted boxes in Fig. 2B). We classified the phenotype of the 1
st
group (nontoxic) and 2
nd group (toxic) of the constitutive-
secretion insertions as class II and class III, respectively (Fig. 2B
and Table 3).
Analyses of the protective epitope in PcrV::EZ with
translocation-competent cytotoxic phenotype (classes I
and III)
In addition to having a role in type III translocation, PcrV is a
clinically important protective antigen. Previously more than 70
monoclonal antibodies were screened for protection against
ExoU-mediated cytotoxicity and only Mab166 was identified as
being protective both in vitro and in vivo [30]. The protective
epitope in PcrV was identified as conformational and the
position of the epitope was mapped to a region between amino
acids 144 and 257 using truncated molecules or between 158 and
217 as assessed by phage display [30]. Mab166 is reactive to the
conformational epitope located in the second globular region
between the central and C-terminal helices, a6a n da11,
respectively (Fig. 1). The location of the protective epitope in
the PcrV-structure models overlaps to the regions identified as
the linear and conformational protective epitopes of LcrV
[39,40].
To determine if this protective epitope was compromised by
EZ-linker insertion, monomer forms of all of the PcrV::EZ
molecules were initially examined for Mab166 recognition.
Western blot analyses demonstrated similar binding of Mab166
to all derivatives, except PcrV::EZ214 (Fig. 3A). EZ214, in which
the linker is located between a-9 and b-4 within the epitope
region, demonstrated a lower affinity for Mab166. Polyclonal
antibody recognizing PcrV bound to all of the EZ derivatives
similarly, including EZ214 (data not shown). In order to analyze
the retention of the protective capacity of Mab166, 22 transloca-
tion-competent mutants were subjected to a hemolysis-based
protection assay. Translocator-mediated lysis of erythrocytes is
inhibited by Mab166 (data not shown and [27]). In the presence of
10 mg Mab166, hemolysis of erythrocytes infected with DV+pcrV
was reduced approximately 70% (data not shown), which was set
as 100% protection. Overall, red blood cells infected with
Table 2. EZ-linker insertion sites and inserted amino acid residues.
mutation site Insertion mapped to amino acid insertion frame inserted amino acid residues
EZ 16 15 1 CLLYTSCGRKMCTRDRFLD
EZ 28 27 1 CLLYTSCGRKMCTRDSASA
EZ 44 43 1 CLLYTSCGRKMCTRDRIVL
EZ 52 52 1 DCLLYTSCGRKMCTRDRLS
EZ 64 63 2 SLVHILRPQDVYKRQAWLL
EZ 77 77 3 AVSCTHLAAARCVQETGLE
EZ 96 96 2 LSLVHILRPQDVYKRQDLR
EZ 101 100 3 VSCTHLAAARCVQETVLVS
EZ 104 104 2 LSLVHILRPQDVYKRQAYF
EZ 105 105 3 PVSCTHLAAARCVQETDFS
EZ 107 107 3 AVSCTHLAAARCVQETGLH
EZ 109 108 1 CLLYTSCGRKMCTRDRHGR
EZ 113 112 1 CLLYTSCGRKMCTRDSDED
EZ 116 115 1 CLLYTSCGRKMCTRDSVIG
EZ 119 119 2 LSLVHILRPQDVYKRQVYK
EZ 120 119 1 CLLYTSCGRKMCTRDSYKD
EZ 131 130 1 CLLYTSCGRKMCTRDRRKA
EZ 134 134 1 DCLLYTSCGRKMCTRDRLD
EZ 138 137 3 VSCTHLAAARCVQETELKA
EZ 154 154 2 LSLVHILRPQDVYKRQQIN
EZ 155 154 1 CLLYTSCGRKMCTRDRINA
EZ 179 179 2 LSLVHILRPQDVYKRQLYG
EZ 180 179 1 CLLYTSCGRKMCTRDRYGY
EZ 198 197 1 CLLYTSCGRKMCTRDRLSN
EZ 202 201 1 CLLYTSCGRKMCTRDRDTF
EZ 204 203 1 CLLYTSCGRKMCTRDSFSG
EZ 214 213 1 CLLYTSCGRKMCTRDSLSG
EZ 279 278 1 CLLYTSCGRKMCTRDRLNR
doi:10.1371/journal.pone.0018356.t002
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of 80% or higher compared to the strain expressing wild-type
PcrV, DV+pcrV (Fig. 3B). For EZ214, which possessed a low
affinity to Mab166 as detected by Western blot analysis, full
protection was observed. For several linker-insertion derivatives,
EZ16, EZ28, EZ52, EZ96, and EZ180, there was slight reduction
(20% or less) in protection. Protection was compromised only for
EZ198 (by 40%, Fig. 3B). This insertion is positioned in the loop
structure next to a-8, which is localized to the middle of the
mapped epitope region (Fig. 1A and B). These data support the
importance of these flexible-loop regions of PcrV for protection
from intoxication.
Mab166 has been shown to bind to surface-localized PcrV and
inhibit the translocon assembly in host membranes, resulting in a
failure to deliver effectors for intoxication [27,30,41]. The binding
of Mab166 to surface-localized PcrV was analyzed by fluorescence
microscopy. First, PcrV was expressed in the DV+pcrV strain and
probed with polyclonal IgG. Spike-shaped signals (shown in green)
Figure 2. Cytotoxicity and secretion profiles of PA103DpcrV host strain complemented with pcrV::EZ-linker constructs. (A) LDH release
from HeLa cells as a quantitative measurement of cytotoxicity during infection. Cell culture supernatants were assayed for LDH activity in triplicate of
two independent experiments for statistical analyses. Representative strains are shown. Error bars indicate SD. (B) Secretory regulation profiles of PcrV
derivatives. Bacterial cells were grown to suppress (2NTA) type III secretion and culture supernatants were subjected to Western blot analyses to
quantify ExoU release. Deregulated ExoU secretion (highlighted by boxes) was quantified based on the amount of constitutively secreted ExoU by
PA103DpcrV vector control (pUCP) as 100%. Deregulated/cytotoxic and deregulated/noncytotoxic phenotypes were shown as dotted and gray boxes,
respectively. Results are representative of at least three independent experiments.
doi:10.1371/journal.pone.0018356.g002
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Bacterial cells were visualized by staining DNA molecules with
DAPI (shown in blue, Fig. 3C). Labeling PcrV with both Mab166
(shown in green) and polyclonal IgG (shown in red) resulted in the
intense signals of either antibody or both (shown in yellow, lower
panels in Fig. 3C). For the pcrV-null control strain (DV+pUCP),
only DAPI-stained cells were visible and no PcrV signals were
detected (left panels, Fig. 3C).
Biochemical analyses of nontoxic class II derivatives and
co-expression of PcrV::EZ derivatives with PcrV
The noncytotoxic phenotype observed in six EZ derivatives
indicates that these mutants are defective for translocation of ExoU
into host cells. To characterize these derivatives further, HeLa cells
were infected and then fractionated to analyze the expression and
location of the effector protein [bacterial (b), HeLa cytoplasmic (cell
soluble, cs), or extracellular medium]. Superoxide dismutase 1
(SOD1) serves as a marker for the HeLa cellular fractions. Strain
PA103DexoUexoT::Tc (PA103DUT) expresses none of the known
effectors but possesses an intact T3SS (Table 1). After infection with
PA103DUT expressing a non-catalytic effector protein, ExoU-
S142A, the non-catalytic molecule was localized to bacterial
fractions and mostly to HeLa cell cytoplasmic fractions (Fig. 4A),
confirming that PA103DUT is competent for translocation. After
infection with the nontoxic PcrV::EZ derivatives, ExoU was
undetectable in soluble and insoluble fractions of HeLa cells,
supporting the translocation-incompetent phenotype (Fig. 4A and
data not shown). The bacterial cells were clearly synthesizing ExoU
and PcrV-EZ (Fig. 4A and B). During the infection, ExoU-S142A
and ExoU were released to the cell-culture medium in the absence
of PcrV (DV) and when complemented with EZ-derivatives,
respectively (Fig. 4B). No extracellular ExoU-S142A was detected
in cellular supernatants from a translocation competent (DUT)
strain (Fig. 4B, lane 8), suggesting that the effector-translocation
machinery is tightly controlled and the bridge between the needle
and translocon structures is sealed by PcrV.
The current structural models of the needle-tip complex
indicate that multiple units of the V protein oligomerize on top
of the needle proteins [34,42–44]. Using a Yersinia co-infection
system, Marenne et al. demonstrated that YopB, YopD, and LcrV
are sufficient for channel formation only when these proteins are
expressed and secreted by the same bacterium [45]. To determine
if the translocation-incompetent PcrV derivatives could exert a
dominant effect over wild-type PcrV, six of these proteins were
expressed in the wild-type strain, PA103. The ability to deliver
ExoU by these co-expression strains was identical to the strain
PA103+pcrV in LDH kinetic assays (Fig. 4C). Under inducing
conditions, all of these strains demonstrated a wild-type secretion
pattern of ExoU, PcrV, and PcrV::EZ (+NTA in Fig. 4D). In the
absence of NTA-mediated induction, effector secretion was tightly
regulated by all coexpression strains similar to the PcrV-
complemented strain (–NTA in Fig. 4D). These data suggest that
despite expression and secretion from the same bacterium, the
function of PcrV was not impaired by translocation-incompetent
PcrV::EZ derivatives.
Erythrocytes are often used to identify the formation of T3S
translocon channels based on the release of hemoglobins by
osmotic lysis of cell membranes [27,46]. To determine if the
noncytotoxic phenotype is mediated by an inability of PcrV::EZ
derivatives to form a translocon, erythrocytes were infected with
the nontoxic mutants and measured for hemoglobin release.
Although the type III-competent strains without effector genes
(DUT+pUCP and DUT+pcrV) released hemoglobin, the nontoxic
mutants were not hemolytic (data not shown).
A failure of the nontoxic PcrV::EZ strains to form translocons
and to influence any phenotypic effect of wild-type PcrV upon co-
expression (Fig. 4C and D) implies that the linker insertion
impaired the association of the derivatives with the needle
components. Surface localization of all of the nontoxic EZ
derivatives was 50% or lower than that of PcrV, quantified with
either microscopy (Table 4) or flow cytometry analysis (Fig. 4E).
These data indicate that the linker insertion within or near the
coiled-coil region destabilizes the interaction of the V-tip protein
with the needle apparatus.
Analysis of class III PcrV derivatives with the cytotoxic/
deregulated-secretion phenotype
The class III strains (EZ44, EZ52, EZ64) demonstrated wild-
type levels of cytotoxicity despite possessing the pcrV-null
phenotype of constitutive secretion (Fig. 2 and Table 3). Their
cytotoxic phenotype suggests these derivatives are competent for
the assembly of PopB/PopD translocons in host membranes. We
used an assay to detect the translocon formation in erythrocytes to
determine if these derivative molecules influence the parental
PcrV phenotype in a competitive, additive, or synergetic manner.
When the proteins were expressed in the DV strain, EZ44 and
EZ64 demonstrated a 30% to 35% lower amounts of hemoglobin
release than the pcrV complemented strain (gray bars, Fig. 5A).
Expression of these derivatives in the wild-type strain, PA103,
demonstrated slightly decreased hemolytic activity compared to
the wild-type strains, PA103+pUCP and PA103+pcrV (black bars,
Fig. 5A). In the case of EZ52, the percentage hemolysis was
comparable to the complemented strain (Fig. 5A). Overall, these
results indicate that the translocon can still be deployed by EZ44,
EZ52, and EZ64 albeit at various efficiencies.
We then analyzed the effect of wild-type PcrV on the
constitutive secretion phenotype of class III derivatives. In the
absence of NTA, secretion of ExoU by the co-expression strains
Table 3. Phenotypic classes of PcrV derivatives expressed in the pcrV-null strain.
class strains cytotoxicity effector secretion Characteristics
I EZ16, EZ28, EZ77, EZ96, EZ101, EZ104, EZ105,
EZ107, EZ109, EZ113, EZ116, EZ154, EZ155,
EZ179, EZ180, EZ198, EZ202, EZ204, EZ214
Cytotoxic Regulated wild-type phenotype
II EZ119, EZ120, EZ131, EZ134, EZ138, EZ279 Noncytotoxic Deregulated pcrV-null phenotype
III EZ44, EZ52, EZ64 Cytotoxic Deregulated also deregulated for PopB/PopD
secretion
IV L63A, D133A Delayed cytotoxicity Regulated low secretion of PcrV/PopB/PopD
doi:10.1371/journal.pone.0018356.t003
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Under inducing conditions (2 mM NTA), levels of ExoU secretion
were similar among the co-expression and wild-type strains (SN,
Fig. 5B). Amounts of secreted derivative proteins, especially EZ44
and EZ52, were undetectable or extremely low irrespective of
NTA (SN, Fig. 5B). When proteins within bacterial cells were
probed, co-expression strains possessed similar levels of EZ
derivatives and PcrV in the presence of NTA (bac, Fig. 5B). In
uninduced conditions, the expression of these proteins within
bacteria was low or undetectable (bac, no NTA, Fig. 5B),
suggesting the dominant expression and secretion of parental
PcrV. Analysis of the molecules in this phenotypic group may help
to understand possible differential features of PcrV distinct to
translocation or secretion. To further analyze the deregulated
Figure 3. Characterization of translocation-competent derivative proteins and the expressing strains using a protective
monoclonal antibody, Mab166. (A) Secretion of PcrV and PcrV::EZ derivatives that contain a linker within a predicted epitope region. V-
proteins released into the bacterial culture supernatant under the induced growth condition (+NTA) were detected with Mab166 as a probe.
Concentrated supernatant was titrated (2-fold serial dilution) for immunoblot analysis. (B) Retention of the protective epitope analyzed by using a
hemolysis-based protection assay. Sheep erythrocytes were infected with DpcrV mutants in the presence of 10 mg Mab166. The conformational-
epitope regions of Mab166 are underlined. (C) Localization of PcrV on the bacterial cell surface detected by immunofluorescence microscopy. PcrV
was probed either with rabbit polyclonal IgG alone (shown in green, top panels) or with polyclonal IgG and Mab166 (shown in red and green,
respectively; lower panels). Bacterial cells were stained with DAPI (shown in blue).
doi:10.1371/journal.pone.0018356.g003
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were compared for the localization on the bacterial surface by flow
cytometry. In the absence of NTA (uninduced), all of the
derivatives localized on the bacterial surface similar to PcrV (open
bars, Fig. 5C). EZ44 trended towards less surface localization
compared to other derivatives but was not statistically significant
Figure 4. Analyses of class II mutations contributing to the noncytotoxic/constitutive-secretion phenotype. (A) Translocation profiles
of ExoU by the EZ-linker mutants during HeLa cell infection. After infection, bacterial cells (b) harvested from the cell culture medium and soluble
fractions of HeLa cells (cs) were subjected to Western blot analysis. An anti-SOD antibody was used to detect SOD1 present in HeLa cell soluble
fractions. (B) Western blot analysis of ExoU or ExoU-S142A release into cell culture medium during infection. Expression of PcrV::EZ derivatives or
parental PcrV in bacterial fractions was detected with anti-PcrV IgG. (C) Cytotoxicity profiles of the strains that co-express the nontoxic derivatives
with PcrV. Kinetics of cytotoxicity was measured by LDH release from infected HeLa cells. (D) Immunoblot analysis of secreted PcrV and PcrV
derivatives (+NTA) or ExoU (6NTA). Regulation of ExoU secretion was examined when co-expressed with a chromosomal parental copy of pcrV.
EZ138 contains two cysteine residues in the inserted linker, leading to the extra conformational species observed in the immunoblot (lane 7). (E)
Bacterial surface localization of PcrV and class II derivatives. Surface-localized V proteins were quantified by flow cytometry.
doi:10.1371/journal.pone.0018356.g004
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bacterial cells with surface-localized EZ64 was similar to the
parental control (filled bars, Fig. 5C). Surface localization of EZ44
and EZ52, however, was significantly lower than that of PcrV
(filled bars, Fig. 5C). The surface localization of EZ44 was almost
as low as the negative control, DV+pUCP (Fig. 5C). It should be
noted that EZ44 and EZ52 could form translocation channels in
erythrocyte membranes and demonstrated a parental pattern of
cytotoxicity upon cell contact-mediated type III activation (Fig. 2A
and 5A). These results indicate that linker insertions in EZ44 and
Table 4. Surface localization of PcrV and class II nontoxic derivatives quantified by using immunofluorescence microscopy.
Strain No. of PcrV/derivative positive cells No. of bacterial cells % positive
DV+pcrV 54 192 28.1
DV+pUCP 2 199 1.0
DV+EZ119 19 252 7.5
DV+EZ120 24 205 11.7
DV+EZ131 12 176 6.8
DV+EZ134 24 203 11.8
DV+EZ138 19 200 9.5
DV+EZ279 21 165 12.7
doi:10.1371/journal.pone.0018356.t004
Figure 5. Analysis of class III cytotoxic/deregulated-secretion derivatives possessing a linker insertion in the N-terminal globular
domain. (A) Hemolytic activity of EZ44, EZ52, and EZ64 mutants. The derivative proteins were expressed in the either pcrV-null (DV) or wild-type
(PA103) strain. (B) Regulation of ExoU secretion by PcrV::EZ when the proteins were co-expressed in PA103. Under uninduced or NTA-induced
conditions, the secretion of ExoU and PcrV/derivatives into growth medium (SN) and the expression of V proteins within bacterial cells were
determined by Western blot analysis. (C) Bacterial surface localization of class III derivative proteins. EZ44, EZ52, and EZ64 were expressed in the pcrV-
null strain (DV) in the presence or absence of a secretion inducer, NTA. Surface localization was quantified by flow cytometry. (D) Secretory regulation
of ExoU and translocon proteins (PopB/PopD) by class III derivatives, when expressed in the pcrV-null strain (DV).
doi:10.1371/journal.pone.0018356.g005
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apparatus specifically when low calcium is the activation signal.
Class III derivatives possessing an insertion in the N-terminal
globular region lost the control of effector secretion (Fig. 2B).
Because PcrV is also required for the secretion of translocon
proteins (PopB and PopD), levels of secreted proteins by EZ44,
EZ52, and EZ64 were examined by Western blot analysis.
Secretion patterns of PcrV and the derivatives into growth
medium were similar under either induced or uninduced
conditions, except a slightly reduced secretion of EZ44 in the
presence of NTA (Fig. 5D). The class III phenotype of deregulated
secretion of ExoU was recapitulated for these derivatives (no NTA,
Fig. 5D). Levels of secreted PopB and PopD by all strains were
indistinguishable in the presence of NTA (Fig. 5D). After growth in
the absence of NTA, the complemented strain (DV+pcrV) secreted
PopB and PopD at fairly low levels while the pcrV-null strain and
class III mutants secreted these translocators at high levels similar
to the induced condition (Fig. 5D). These results suggest that the
insertion in EZ44, EZ52, and EZ64 disrupts the low-calcium
dependent control of the secretion mechanism for both effector
and translocon proteins.
Cytotoxic phenotypes of single site-specific mutations
(class IV)
Two linker sites, representing the constitutive-secretion/cyto-
toxic phenotype (EZ64) and the constitutive-secretion/noncyto-
toxic phenotype (EZ134), were selected for site-directed mutagen-
esis. Alanine was used to replace a leucine residue at position 63
(L63A) and an aspartic acid residue at position 133 (D133A).
When LDH release was monitored during an infection, both site-
specific mutants appeared to have a delayed-cytotoxic phenotype
and classified to the forth phenotypic group, class IV (Fig. 6A and
Table 3). The time lag prior to the intoxication by these mutants
was approximately 1 h, and after the lag period, the kinetics of
LDH release was similar to the complemented strain (Fig. 6A).
Formation of translocation channels in eukaryotic plasma
membranes by effectorless strains can be detected by measuring
osmotic lysis via the release of LDH from infected cells [45,47]. To
monitor translocon formation in the HeLa cell membrane, the
release of LDH was measured at 7 h post-infection with various
strains of P. aeruginosa. HeLa cell infection with a T3SS competent
and effectorless strain, PA103DUT+pUCP, demonstrated a
statistically significant level of LDH release (p,0.001 by t-test,
Fig. 6B). Strain PA103exsAV is unable to express the T3SS due to
a mutation introduced into a key transcriptional activator, ExsA
(Table 1) [7,48]. Release of LDH was undetectable after infection
with this strain (Fig. 6B). Collectively, these data support the
hypothesis that lysis of HeLa cells in the absence of effectors
requires the intact T3SS.
To determine whether the cytotoxic phenotype was specifically
related to an intact translocation operon, translocator-deletion
mutants PA103DpcrV and PA103DpopB were compared to
PA103DUT in the presence or absence of an inhibitor of actin
polymerization, cytochalasin D (Fig. 6B). Viboud and Bliska
demonstrated that treatment with cytochalasin D reduced type III-
mediated osmotic lysis of eukaryotic cells during infection with
Yersinia [47]. Protection by this inhibitor is mediated by the
prevention of local actin rearrangements at the insertion sites of
YopB/YopD translocons, where cytochalasin D is postulated to
suppress disruptive membrane movement [47]. When cells were
infected with translocator-deletion mutants, DpcrV and DpopB,
LDH release was at a basal level similar to the T3S incompetent
strain, PA103exsAV (Fig. 6B). When cytochalasin D-treated cells
were infected with an effectorless strain of P. aeruginosa, LDH
release was ameliorated (DUT+pUCP in Fig. 6B), indicating that
the observed LDH release is due to membrane disruption caused
by insertion of PopB/PopD translocons. Complementation of
translocator-deletion mutants, DV+pcrV and DpopB+popB, allowed
intoxication with ExoU even in the presence of cytochalasin D
(Fig. 6B). The inhibitor treatment did not interfere with the
translocation of effectors (Fig. 6B and [49],[50,51], suggesting that
cytochalasin D does not inhibit insertion of translocons into the
eukaryotic membrane. These results confirm that both PopB and
PcrV translocators are required for the channel formation
followed by translocation of the effector.
The delayed-toxic phenotype of class IV mutants could be
mediated by the inefficient formation of translocons in the host
plasma membrane. At 7 h post infection of HeLa cells, the point
mutants released intermediate levels (,60%) of LDH, not as high
as the fully toxic strains but not as low as the effectorless type III-
competent strain, DUT+pUCP (gray bars, Fig. 6C). The
intermediate levels of LDH release by both point mutants were
partially inhibited by the addition of cytochalasin D (black bars,
Fig. 6C). This inhibitor could not reduce ExoU-mediated LDH
release even at early stages of cellular intoxication (data not
shown). These data suggest that class IV mutants are capable of
forming translocons but the slow kinetics of the channel formation
allows cytochalasin D to be effective prior to ExoU translocation.
Biochemical analyses of class IV mutations for translocon
formation and secretory regulation
HeLa cell infection with DV+L63A and DV+D133A strains
demonstrated the delayed-cytotoxicity phenotype (Fig. 6A and C).
The release of LDH by these strains was partially inhibited by
cytochalasin D (Fig. 6C), suggesting that the low expression or
slower deployment of translocon proteins (PopB and PopD) due to
the alanine substitution. To determine if L63A and D133A
proteins are adequately expressed and associated with the type III
needle, bacterial surface localization of the derivatives was
analyzed by flow cytometry. The number of bacterial cells with
surface localized L63A and D133A was comparable to the
parental control, irrespective of the presence of NTA (Fig. 7A).
These results implicate that the delayed-cytotoxic phenotype is
related to a malfunction of these derivatives other than insufficient
protein expression or surface localization.
To evaluate the formation of translocon channels in mem-
branes, sheep erythrocytes were infected with a point-mutation
strain DV+L63A or DV+D133A. Infection with either of the
strains released only basal levels of hemoglobin, similar to the pcrV-
null strain at a 1 h incubation time (gray bars, Fig. 7B). The
hemolysis data along with the delayed cytotoxic effect on HeLa
cells (Fig. 6A and C) suggest a slower rate of the insertion and
assembly of translocons in host membranes by these mutants. Co-
expression of the derivatives with PcrV in the parental PA103
strain restored hemolytic activity to the levels of positive control
strains (filled bars, Fig. 7B). These results indicate that L63A and
D133A derivatives do not possess a dominant negative effect on
the translocon assembly by parental PcrV.
Class IV derivatives appeared to require additional time for the
assembly of translocation channels, which can be mediated by low
expression or secretion of translocator proteins. For the point
mutants, PcrV, PopB, and PopD were similarly expressed and
retained within bacterial cells at the level of the DV+pcrV strain
under induced and uninduced conditions (bacteria, Fig. 7C). In
contrast, levels of secreted PcrV, PopB, and PopD by these
mutants were significantly reduced (supernatant, Fig. 7C). Nota-
bly, secreted PopB and PopD proteins were undetectable in the
absence of NTA (no NTA, Fig. 7). In a calcium-rich environment,
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L63A, and D133A and the regulatory system was perturbed only
when pcrV was deleted (no NTA, Fig. 7C). Under low-calcium
inducing conditions, most of expressed ExoU was secreted into the
growth medium and barely detectable in bacterial cell fractions of
all four strains (2 mM NTA, Fig. 7C). These data suggest that the
alanine substitution at L63 or D133 decreases the efficiency of
translocator secretion, resulting in the slow translocon assembly
and delayed-cytotoxic phenotype.
Discussion
The T3SS is a key virulence determinant of P. aeruginosa and
multiple other Gram-negative organisms. Understanding the
essential components and functional mechanisms of this intoxica-
tion system will be important for the development of novel
therapeutics that could inhibit translocon assembly, toxin
translocation, and signaling activity associated with transcriptional
induction in response to contact with eukaryotic cells [33,52–54].
This study focuses on a linker-scanning mutagenesis analysis of
PcrV, the needle-tip protein of the P. aeruginosa type III apparatus.
Despite the molecular, biochemical, and microscopic analyses of
the tip complexes in the past, the multifunctional nature of tip
proteins makes it difficult to tease out how they mechanistically
serve as regulators for expression and secretion of effectors as well
as extracellular chaperones for integration of the hydrophobic
translocators (PopB and PopD) into eukaryotic plasma mem-
branes. Understanding the functional mechanism of the needle-tip
proteins is particularly relevant to the design of vaccines and
therapeutics targeted to neutralize activities that contribute to
intoxication of host cells [29,33,55–57].
The linker-scan analysis of PcrV was initiated as an unbiased
approach to cause distinct 19 amino-acid insertions in this
molecule. The lower frequency of C-terminal insertions does not
correlate with the selection process relative to protein expression as
the clones were screened in E. coli, a host in which the Pseudomonas-
Figure 6. Cytotoxicity profiles of class IV site-specific mutants compared to linker-insertion strains. (A) LDH release comparison of the
point mutants (L63A and D133A) and the strains containing an EZ-linker insertion in adjacent sequence locations. (B) Cytotoxic effects on HeLa cells
caused by formation of type III translocation channels at 7 h post-infection. LDH release from HeLa cells infected with PA103DV+pUCP, DV+pcrV,
DUT+pUCP (competent type III injectisomes without the expression of any effectors) and PA103exsAV+pUCP (type III incompetent). The popB–
deletion mutant and its complemented strain were used to represent the effect of a translocon protein on cytotoxicity. LDH release was tested in the
presence (black bars) or absence (gray bars) of cytochalasin D (3 mg/ml). Cytochalasin D was added to examine the effect on the type III channel-
mediated cytotoxicity and ExoU-mediated killing. *p,0.001 by t-test, compared to DV+pUCP. (C) The effect of cytochalasin D on the delayed
cytotoxicity of class IV mutants. Cytotoxicity was measured and presented as (B).
doi:10.1371/journal.pone.0018356.g006
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the insertions (,79%) did not disrupt the function of effector
translocation, retaining the cytotoxic phenotype of the strains.
Amino acid sequences within the insertion grouped into 3 patterns
flanked by various sequences due to the target site duplication
(Table 2). Each group of linkers contains either 3 cysteine residues,
2 cysteine residues, or a proline residue, which may introduce a
circular or folded structure of an EZ linker by a formation of
disulfide bonds or a proline kink in the middle of the linker. PcrV
possesses no cysteine residues to form a covalent bond with a free
cysteine in the linker. Biochemical and biological analyses of the
linker-insertion derivatives identified four types of phenotypic
groups possessing distinct structural and functional regions of PcrV
(Table 3 and Fig. 8).
Class I insertions (wild-type phenotype; Figure 8A)
Most of the insertions for this phenotypic group are mainly
positioned in N- and C- terminal globular domains, except EZ154
and EZ155 (Table 3 and Fig. 8A). These two insertions are located
at the tip end of the central coiled-coil structure, less likely involved
in the coiled-coil interaction. Collectively, both N- and C-terminal
globular domains are more permissive to insertions, indicating the
structural flexibility in those domains.
PcrV is a clinically important molecule as an effective protective
antigen for P. aeruginosa infection. All of the PcrV::EZ proteins
were immunoreactive to Mab166 examined by Western blot
analysis, except EZ214. Using an erythrocyte-protection assay, we
demonstrated that most of the translocation-competent mutants
retain the conformational protective epitope. Mab166 protected
against infection with the strain expressing EZ214, suggesting the
epitope in this molecule is preserved during bacterial contact with
erythrocytes. Reduced protection for EZ198 is understandable
since the linker-insertion site is located within the predicted
epitope region. These protection and biochemical data indicate
that the loop regions proximal to short helices (a8 and a9) are
critical for the recognition and protection by Mab166 and that the
epitope region appears to be structurally flexible and retains the
protective role irrespective of the 19-residue insertions.
Figure 7. Biochemical analyses of class IV derivatives containing a point mutation. (A) Bacterial surface localization of the derivatives
containing an alanine substitution quantified by flow cytometry. L63A and D133A proteins were expressed in the pcrV-null strain (DV) in the presence
or absence of NTA. (B) Measurement of hemolytic activity of the pcrV-point mutants. Sheep erythrocytes were infected for 1 h with either PA103 or
the DV strain expressing the L63A or D133A derivative. (C) Regulation of effector and translocator secretion by class IV derivatives expressed in the
pcrV-null strain (DV). Under the uninduced (no NTA) or induced (2 mM NTA) condition, proteins secreted into growth medium (supernatant) were
detected by Western blot analysis. Expression of the proteins within bacterial cells was shown as comparison (bacteria).
doi:10.1371/journal.pone.0018356.g007
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The pcrV-knockout deletion in the chromosome of PA103 loses
the regulatory function for both secretion and translocation of
effectors, resulting in a failure to intoxicate host cells and
constitutive secretion of effector proteins into a growth medium.
The regulatory mechanism of T3SS is complex. It has been
proposed that there are multiple-levels of control by the needle-tip
complex, needle proteins, and cytosolic regulators located around
the base of a type III apparatus [28,42,45,59–61]. For example,
cytoplasmic chaperones for PcrV and LcrV (PcrG and LcrG,
respectively) are involved in secretory regulation of P. aeruginosa
and Yersinia species [59,60]. In the case of P. aeruginosa strain
PAO1, a deletion of either pcrV or pcrG leads to a calcium-blind
secretion phenotype, and the deregulation effect is additive for the
double-deletion mutant [60]. In Yersinia species, YopN with its
adaptor TyeA also acts as a cytoplasmic regulator in addition to
LcrG [28,45]. Moreover, it is postulated that needle proteins are
involved in conducting an activation signal bidirectionally to
coordinate the regulation of T3SS [42,61]. Further studies are
needed to elucidate how the secretion and translocation
mechanisms are intricately accommodated by various regulatory
proteins present in distinct locations.
The class II deregulated-secretion/translocation phenotype
observed when pcrV is deleted from strains PA103 and PAO1 is
recapitulated in Shigella species when the V-like gene, ipaD,i s
deleted [60,62,63]. In contrast, a knockout or partial deletion of
pcrV in P. aeruginosa CHA and PAK strains or the lcrV gene in
Yersinia species retains the regulated-secretion phenotype despite
the loss of cytotoxicity [25,64–66]. This phenotypic diversity may
be specific to the strain [24] or the size and region of the deletion if
the entire gene is not deleted.
Our data demonstrated that the inability to deliver effectors by
class II mutants is due to a failure of the PcrV derivatives to
localize on the bacterial surface. The results suggest that class II
derivatives form a structurally unstable complex possessing a low
affinity to the needle apparatus or they are unable to oligomerize
to form a needle-tip complex. We expressed class II derivatives in
a wild-type host background with the expectation of hetero-
oligomer formation with PcrV. The attenuated affinity of the
derivative proteins for the needle structure, however, allowed wild-
type PcrV to be functionally dominant, selecting for parental
phenotypes during co-expression.
An insertion region that contributes to the class II phenotype is
mapped to the end of N-terminal globular domain (EZ119,
EZ120) and at the base of the intramolecular antiparallel coiled-
coil structure (EZ131, EZ134, EZ138, EZ279) shown in Fig. 8B
[34]. Many residues conserved in both PcrV and LcrV are located
on the helices that form the coiled-coil structure, suggesting a
structural importance in these regions. Caroline et al. showed that
one of their site-specific mutations (L276A) in one of the coiled-coil
Figure 8. PcrV tertiary structure models indicating the insertion/mutation sites responsible for the phenotypic class. (A) Class I
insertions: the wild-type cytotoxic/regulated-secretion phenotype. The residue, at which an EZ-linker is inserted, is shown in black. (B) Class II
insertions: the pcrV-null noncytotoxic/deregulated-secretion phenotype. (C) Class III insertions: cytotoxic/deregulated-secretion phenotype. The linker
is inserted within the N-terminal globular domain. (D) Class IV mutations: delayed-cytotoxicity/regulated-secretion phenotype. Although secretion of
an effector protein is well controlled, the secretion levels of translocators (PcrV derivative, PopB, and PopD) are decreased by a single amino-acid
substitution.
doi:10.1371/journal.pone.0018356.g008
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macrophages in vitro [23]. Lee et al. demonstrated that single
amino acid replacement of the F279 residue of PcrV to arginine
abolishes the cytotoxic phenotype [60]. Combined with our data,
hydrophobic residues in this region of PcrV must be critical for
stabilizing the structure. Interestingly, the intramolecular coiled-
coil motif is also seen in structural analyses of the needle subunit
proteins, suggesting a common mechanism of assembly of tip
proteins and needle subunits [28]. The C-terminal a-helix of
LcrV, one of the coiled-coil helices, is structurally homologous to a
stabilizing helix of the Shigella needle protein (MxiH), which
permitted the modeling of the LcrV-pentamer tip complex on the
top end of the MxiH needle without structural restraints [42].
Thus, we suggest that the disruption of the coiled-coil structure by
a linker insertion leads to a failure to assemble or to position the V-
tip complex on the type III needle, resulting in the class II pcrV-null
phenotype.
Class III insertions (cytotoxic/deregulated-secretion
phenotype; Figure 8C)
Insertions between amino acids 44 and 64 of PcrV imparted the
class III phenotype of cytotoxicity with constitutive secretion
(Table 3 and Fig. 8C). Insertions in this area compromised the
secretory regulation of the effector, ExoU, as well as translocon
proteins, PopB and PopD. Despite of the defect in secretory
control, the derivatives (EZ44, EZ52 and EZ64) retained the
capability to assemble translocons and translocate the effector,
resulting in wild-type levels of cytotoxicity. This secretory-control
region is located within an N-terminal globular domain, which is
involved in associating with the needle proteins as it is part of the
base of the V-tip complex [34]. Our flow cytometry analysis
demonstrated that EZ44 and EZ52 molecules are localized on the
bacterial surface in the uninduced environment but delocalized in
low-calcium induced conditions. These data suggest that this
region is involved in the mechanical control of the type III
apparatus responding to environmental signals. Intriguingly, the
insertion is tolerated for translocation events, suggesting that
different conformations of PcrV exist for secretion and transloca-
tion functions. We postulate that the conformations of this needle-
tip protein are distinct in response to the activation stimuli of the
type III machinery specific to contact-dependent translocation (a
well-coordinated process with tightly sealed transport of effectors)
or chelator-induced secretion (less-controlled release of transloca-
tors and effectors).
Structural changes within this N-terminal region may influence
the regulation of the opening/closing of the tip complex in
addition to the affinity of the tip protein for the injection needle
[42,65,67–69]. Furthermore, the conformation of the V proteins
for translocation processes may be distinct to each stepwise
function, such as insertion of translocators into membranes,
assembly of a translocon, and delivery of effectors. Our data
support a model in which PcrV secretes translocators at a basal
level but not an effector until receiving a signal based on the host
contact or low calcium environment [28,49]. Elper et al. and others
demonstrated that IpaD, a tip protein in Shigella, senses small
molecules (deoxycholate or other bile salts) that stabilize the
translocator complex prior to T3SS induction [70,71].
The deregulated-secretion phenotype of class III derivatives is
overpowered by functional PcrV when proteins are co-expressed
in wild-type PA103, resulting in tightly regulated secretion of
ExoU. It is notable that the amount of secreted derivative proteins
is significantly lower than that of PcrV even though the expression
levels of all proteins are equivalent. When the derivatives were
expressed in the pcrV-null host strain, secretion of these proteins
was not inhibited. These data imply that wild-type PcrV is a
preferred substrate for the secretion machinery and regulators
involved in protein export.
The tip complex formed by the derivatives, EZ44, EZ52 and
EZ64, is competent to control the insertion of the hydrophobic
translocators in host plasma membranes and the assembly of the
translocon structure. For the needle-tip proteins from Shigella
(IpaD) and Burkolderia (BipD), the N-terminal domain is believed to
function as an intramolecular chaperone to control the timing of
self-oligomerization [72]. However, the structure of the N-terminal
domain of PcrV and LcrV is bulky and has few structural
similarities to IpaD and BipD [72]. In addition, no chaperones
specific to IpaD and BipD have been found, while PcrV and LcrV
have the cognate chaperones PcrG and LcrG that are expressed
from the same operon. It is postulated that PcrV and LcrV act as
chaperones for translocon proteins [27]. Specific domains of PcrV
may perform chaperone functions to control the self-oligomeriza-
tion of PcrV and assemble the PopB/PopD translocon in the
eukaryotic membrane. More studies are needed to test these
hypotheses.
Class IV mutations (delayed-cytotoxicity/
regulated-secretion phenotype; Figure 8D)
Site-specific alanine substitutions (L63A and D133A) made in
two regions of PcrV demonstrated a class IV delayed-cytotoxic
phenotype (Table 3 and Fig. 8D). In this case, we believe that
translocon proteins are deployed and that translocation of ExoU
occurs as cytotoxicity is observed even in the presence of
cytochalasin D. At the late time point of HeLa cell infection,
levels of LDH release by these mutants are higher than by an
effectorless type III-competent strain, indicating that cytotoxicity is
mediated by the formation of translocation channels and the
enzymatic activity of translocated ExoU. It is unclear why a site-
specific lesion (L63A) delayed in the induction of cytotoxicity
relative to the linker counterpart (EZ64), which has a cytotoxic
phenotype. The leucine at residue 63 is conserved and positions
next to an LxxLxxL zipper motif, which is implicated for the
interaction with other molecules, possibly a needle protein. The
other residue, D133, is located within another leucine motif
(Lx3Lx2Lx3L) important for the formation of the intramolecular
coiled-coil structure [73].
Co-expression analysis of class IV derivatives with PcrV
demonstrated the retention of the parental phenotype. L63A
and D133A molecules may not oligomerize with themselves or
with PcrV due to a loss of a hydrophobic- or charged-side group in
the residue by alanine substitution. Amounts of the derivatives
secreted by these mutants were extremely low, which may explain
the dominant effect of wild-type PcrV on translocon assembly at
the initial stage of erythrocyte infection. The alanine replacement
may also influence the association of PcrV with its cognate
chaperone, PcrG, in the bacterial cytoplasm. It is postulated that
the interaction between PcrV and PcrG facilitates the export of
PcrV, yet the interaction is not required for the secretory
regulation of effectors [60]. If the affinity to PcrG is decreased,
the PcrV derivatives may be inefficiently unfolded prior to the
export process, leading to the delayed establishment of translocon
structure and effector translocation.
Our biochemical analyses indicated that the expression
patterns of all of the translocators and the surface localization
of the V derivatives are similar to those of PcrV. However,
secretion levels of translocators, especially translocon proteins
PopB and PopD, were extremely low regardless of the presence
or absence of NTA. Erythrocytes infected with these point
mutants did not release hemoglobin during the 1 h-incubation
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Once translocons were formed, the kinetics of ExoU-mediated
cytotoxicity was equivalent to the parental strain. It is intriguing
that the delayed-secretion phenotype specific to translocator
proteins was also observed with an mxiC mutant in Shigella [61].
MxiC is a cytoplasmic regulator for a Shigella type III system,
which belongs to the family of YopN/TyeA in Yersinia.A
knockout mutant of mxiC constitutively secretes effectors but the
secretion of IpaC, a PopD ortholog translocator, is weak and
delayed upon type III induction [61,74]. These phenotypic
properties combined with our data suggest that the control of
type III machinery is coordinated specific to the type of secretion
substrates, either translocators or effectors. Further studies are
needed to elucidate the control mechanisms of the T3SS distinct
to translocators and effectors.
Conclusions
Comprehending how the needle-tip complex interfaces with the
type III machinery and the translocon assembles in eukaryotic
membranes will be important towards understanding the T3SS-
mediated intoxication mechanisms and protective nature of
antibodies to V antigens. The tertiary structure models of tip
proteins provide a template to design V antigens that retain
immunogenicity but lack immunosuppressive properties [55,75].
We isolated the strains with interesting biological and biochemical
phenotypes: constitutive secretion with cytotoxicity, delayed
cytotoxicity, delocalization of the tip protein only upon low-
calcium induction, and low secretion levels of translocators but not
of effectors. Further analyses of PcrV and the derivatives
compared to the homologous tip proteins in the Ysc family, LcrV
(Yersinia) and AcrV (Aeromonas), as well as those belonging to other
families, IpaD (Shigella), BipD (Burkolderia), SipD (Salmonella), and
EspA (enteropathogenic E. coli), will advance a mechanistic
understanding of how these molecules function in the secretion,
translocation, and intoxication processes. Furthermore, it is
important to elucidate the control mechanism of the type III
system, which is coordinated by V-like proteins, cytoplasmic
regulators, and needle proteins. The functional and regulatory
information of this multifunctional translocator, PcrV, will
facilitate the development of new-generation vaccines and
therapeutics targeting on type III-mediated intoxication of host
cells.
Materials and Methods
Bacterial strains and growth in bacteriological medium
P. aeruginosa strains used in this study are shown in Table 1. The
TransforMax
TM EC100
TM Escherichia coli strain (F
2 mcrA D(mrr-
hsdRMS-mcrBC) Q80dlacZDM15 DlacX74 recA1 endA1 araD139
D(ara, leu)7697 galU galK l
2 rpsL nupG) from EpiCentre was used
in this study. P. aeruginosa strains were cultured on Vogel-Bonner
minimal medium [76] agar plates in the presence or absence of
400 mg/ml carbenicillin at 37uC. E. coli strains were cultured on
Luria agar plates or broth supplemented with 50 mg/ml
kanamycin, and/or 100 mg/ml ampicillin as required.
Random mutagenesis by linker insertion
Random mutagenesis of pcrV was performed using the
EZ::TN
TM In-Frame Linker Insertion Kit, according to manu-
facturer’s instructions (EPICENTRE). The plasmid pUCP-pS-
pcrV,a nE. coli-Pseudomonas shuttle vector carrying pcrV under the
control of the exoS promoter (pS, [29]), was used as template DNA
for the in vitro transposition reaction. After the transposition, the
reaction mixture was electroporated into E. coli and grown on
Luria agar containing 50 mg/ml kanamycin and 100 mg/ml
ampicillin to select for clones carrying transposed plasmids.
Plasmid DNA was prepared and subjected to restriction mapping
and DNA sequence analysis using primers FP-2 and RP-2
provided in the linker insertion kit to determine the site of
insertion of the EZ::TN
TM ,NotI/KAN-3. transposon in the pcrV
coding region. Plasmids carrying insertions in pcrV were subjected
to NotI digestion and re-ligation to remove all but 57-base pairs of
insertion-derived sequence resulting in the in-frame insertion of 19
codons into pcrV. Each resolved clone was subjected to DNA
sequence analysis to confirm the in-frame insertion. Plasmids
carrying the 19-codon insertion in pcrV were transformed into P.
aeruginosa strains, PA103DpcrV or PA103.
Site specific mutagenesis
Plasmid, pUCP-pS-pcrV was purified using a Qiagen miniprep
kit. Plasmid DNA was mutagenized using Change-IT
TM kit (USB).
Primers used are (underline shows difference from wild-type
sequence):
L63A: 59-TCAAGGCGCTCGCCTGGTTGGCCGCGGC-
CAATCCGTCCGCGC-39
D133A: 59-CAAGCGCAAGGCGCTGCTCGCCGAGCTC-
AAGGCGCTGACCG-39
Colony screening PCR and restriction enzyme digestion of the
plasmids were used to select point mutants of interest. The
mutations were confirmed by DNA sequencing analyses.
Expression and controlled secretion of type III proteins in
bacterial culture
P. aeruginosa strains were grown in Luria broth (LB) containing
400 mg/ml carbenicillin in the presence (inducing condition) or
absence (non-inducing condition) of 2 mM NTA. Culture
supernatant was separated from bacterial cells by centrifugation
and subjected to ammonium sulfate precipitation [37]. After
precipitation, the concentrated proteins were normalized to an
equivalent OD540 by suspending in SDS-PAGE sample buffer.
Protein structure modeling
The amino acid sequence of PcrV from strain PA103 used in
this study was submitted to Swiss Model server (Automated
Comparative Protein Modeling Server, http://swissmodel.expasy.
org). The structural data of the ortholog LcrV from Yersinia (PBD:
1r6f chain A) was used as a template for modeling. The Swiss-Pdb
Viewer 4.0 was used to indicate the sites of the linker insertion in
the PcrV structural model [36]. For coloring, the secondary
structure succession mode was used to distinguish alpha-helices
and beta-sheets. LcrV sequence from Y. pestis strains KIM 10
(NP_857946 and NP_857751) and Z176003 (YP_003560525) was
used for alignment.
Western blotting
For detection of specific proteins, samples were separated by
SDS-PAGE, transferred to nitrocellulose membranes, and probed
with rabbit anti-PcrV IgG, sheep anti-SOD IgG (CalBiochem),
rabbit anti-PopD IgG, or mouse anti-ExoU monoclonal antibody
U29F8. PopB was detected with a mouse monoclonal antibody
produced by using a transmembrane domain-deleted molecule (a
gift from Dr. Joseph T. Barbieri, Medical College of Wisconsin).
As a secondary antibody, horseradish-peroxidase conjugates for
rabbit IgG (Sigma), sheep IgG (Jackson), or mouse IgG (Roche)
were used to detect the appropriate primary antibody. SuperSignal
West Pico Chemiluminescent Substrate (Pierce) was used for
detection of immuno-reactive proteins. Signals from Western blot
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mager AIC (Alpha Innotech) for densitometry.
Lactate dehydrogenase (LDH) release assays to measure
cytotoxicity
HeLa cells were grown in 6-well tissue culture plates to
approximately 6610
5 cells per well. Bacterial cells suspended in
serum-free DMEM were added for infection with an MOI of 5.
When required, HeLa cells were pre-incubated for 30 min in
serum-free DMEM containing 3 mg/ml cytochalasin D prior to
and during infection. To follow the release of LDH over time,
30 ml aliquots of the tissue culture supernatant were removed at
various time points and subjected to centrifugation. The
supernatant was diluted in serum-free DMEM and LDH activity
was measured using the CytoTox 96H Non-Radioactive Cytotox-
icity Assay (Promega) according to the manufacturer’s instructions.
Percent cytotoxicity was calculated using PA103DpcrV+pUCP-pS-
pcrV as the maximum reference and uninfected samples as the
baseline. Assays were performed at least 3 times as independent
experiments and the error bars indicate standard deviations.
Expression and localization of PcrV in the HeLa cell
infection model
HeLa cells (2610
6 cells) were seeded in a 60 mm cell culture
dish and incubated at 37uCi n5 %C O 2 overnight. HeLa cell
monolayers were washed twice with HBSS and incubated in
serum-free DMEM for 15 to 20 min. Bacterial cells were
suspended in serum-free DMEM and used at an MOI of 5 for
in vitro infections. After infection for 3 to 4 h, the culture medium
containing bacteria was removed and subjected to centrifugation
at 5,9006g for 10 min to isolate bacterial cells. The proteins in the
supernatant were concentrated by ammonium sulfate precipitation
for immunoblot analysis. The infected HeLa monolayers were
washed with PBS twice and then 500 ml Triton solution (0.05%
Triton X-100 and 10 mM EDTA in PBS) was added for
fractionation. Cells were scraped and transferred into a micro-
centrifuge tube. The culture dish was rinsed with additional 100 ml
of Triton solution to complete the harvesting of cells. Harvested
cells were incubated at room temperature (RT) for 30 min and
briefly vortexed several times during the incubation period. The
insoluble fractions were collected by centrifugation at 16,1006 g
for 15 min at RT. The supernatant (soluble fractions) represents
cellular cytosolic and translocated bacterial proteins.
Hemolysis assay and erythrocyte protection by Mab166
The hemolysis and protection assays were performed based on
modified protocols from Blocker et. al. and Goure et al. [27,46].
Sheep red blood cells (RBCs, PML microbiologicals) were washed
and stored in 5 mM glucose in PBS. Bacterial cells were grown in
LB at 37uC for 3 h, washed and suspended in 5 mM glucose in
PBS prior to infection. A mixture of 5610
7 RBCs and 2.5610
7
bacterial cells (MOI of 0.5) was suspended in the total volume of
200 ml in 0.5 ml microcentrifuge tubes. The samples were
subjected to centrifugation at 1,0006 g for 10 min at RT and
then incubated at 37uC for 1 h. After incubation, RBCs and
bacteria were subjected to centrifugation and 150 ml of superna-
tant was used to assess released hemoglobin as measured by
absorbance at 415 nm (SpectraMax M5 by Molecular Devices).
To evaluate the protection of RBCs by the monoclonal antibody,
10 mg of MAb166 was incubated with bacterial cells at RT for
45 min and followed by the addition of RBCs for the hemolysis
assay. Protection of erythrocytes was calculated by the formula:
% protection~ hemolysis inthe absence of Mab166 ðÞ { ½
hemolysis in the presence of Mab166 ðÞ   = hemolysis in the ð
absence of Mab166Þ|100
Assays were performed at least 3 times and the error bars indicate
standard deviations.
Surface localization of PcrV derivatives
The flow cytometry procedure used was modified from the
method reported by Lee et al. [60]. Bacterial cells (initial OD540 of
0.1) were grown in LB containing 400 mg/ml carbenicillin in the
presence or absence of 2 mM NTA at 37uC for 2.5 h. Cells were
collected from 1 ml of culture by centrifugation at 1,3006 g for
4 min, suspended in 250 ml PBS, and gently mixed by pipetting.
For fixation, the same volume of 4% para-formaldehyde in PBS
was added and incubated on a rotator for 25 min at room
temperature. The reaction was quenched by addition of 25 mlo f
1 M Tris-HCl (pH 8) followed by an incubation for 5 min. Fixed
cells were washed with PBS and then blocked with 500 ml of 10%
fetal bovine serum (FBS) in PBS for 1 h. V-tip protein localization
on the bacterial cell surface was measured by assessing the binding
of a rabbit anti-PcrV IgG (1:500) for 1 h. The binding step was
followed by two washes with 10% FBS/PBS. Cells were labeled
with an Alexa Fluor 488-conjugated anti-rabbit IgG (1:2,000,
Invitogen) for 1 h and washed with 10% FBS/PBS once and then
with PBS once. Bacterial cells were subjected to centrifugation and
suspended in 750 ml of PBS. The samples were diluted at 1:200
with PBS prior to flow cytometry analysis using Guava easyCyte
6HT (Millipore). Samples were prepared in duplicate from at least
two independent experiments for statistical analyses with SD. For
fluorescence microscopy, immunoprobed cells were analyzed with
Nikon Eclipse Ti-U inverted microscope with Chroma Sedat filters
using a 1006oil immersion objective lens. NIS-Elements software
(Nikon) was used for image acquisition. To quantify the surface
localization of PcrV, 12 field images were randomly captured for
each sample and then the number of bacterial cells possessing the
signals of PcrV was compared to the number of DAPI-stained
bacterial cells.
Supporting Information
Figure S1 Bacterial expression levels of class II and III
derivatives with constitutive- secretion phenotype. Ex-
pression of class II and III derivatives and parental PcrV within
the pcrV-null strain was analyzed after growth in non-inducing (2
NTA) and inducing (+ NTA) conditions.
(TIF)
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